Crossing the Valley of Death: The Translational Crossing the Valley of Death: The Translational Funding and Management Gap Funding and Management Gap Moderator: Sharon Begley, Science Editor, Newsweek Panelists: • Robi Blumenstein, President, CHDI Management/CHDI Foundation • Randall Carpenter, Co-Founder, President and Chief Executive Officer, Seaside Therapeutics • Dennis Purcell, Managing Partner, Aisling Capital • Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network • Christian Loucq, PATH Malaria Vaccine Initiative
Valley of Death Panel Slides at the Partnering for Cures Conference, December 2, 2009
Nov 22, 2014
A panel at the inaugural Partnering for Cure conference spotlights the translational funding and management gap in biomedical research and development.
Moderator: Sharon Begley, Science Editor, Newsweek
Panelists:
Robi Blumenstein, President, CHDI Management/CHDI Foundation
Randall Carpenter, Co-Founder, President and Chief Executive Officer, Seaside Therapeutics
Dennis Purcell, Managing Partner, Aisling Capital
Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network
Christian Loucq, PATH Malaria Vaccine Initiative
Moderator: Sharon Begley, Science Editor, Newsweek
Panelists:
Robi Blumenstein, President, CHDI Management/CHDI Foundation
Randall Carpenter, Co-Founder, President and Chief Executive Officer, Seaside Therapeutics
Dennis Purcell, Managing Partner, Aisling Capital
Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network
Christian Loucq, PATH Malaria Vaccine Initiative
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Crossing the Valley of Death: The Translational Funding Crossing the Valley of Death: The Translational Funding and Management Gapand Management Gap
Moderator: Sharon Begley, Science Editor, Newsweek
Panelists:• Robi Blumenstein, President, CHDI Management/CHDI Foundation• Randall Carpenter, Co-Founder, President and Chief Executive Officer,
Seaside Therapeutics• Dennis Purcell, Managing Partner, Aisling Capital• Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network• Christian Loucq, PATH Malaria Vaccine Initiative
Brain Developmental
Disorders
Translating the mGluR Theory into Novel Therapeutics
Scientific Discovery
Druggable Targets
Efficacy in Model System
Candidate Drug
IND-enabling Research
Human Trials
Seaside Therapeutics Model
• Venture Philanthropy Seed Funding
• Core Competency in Translational Medicine
• Collaborative Business Model– Foundations – FRAXA, Autism Speaks, NFXF
– Merck & Co, Inc. – R&D Collaboration
– NIH UO1 Translational Research Cooperative Agreement• NIMH, NICHD, BPCA, NINDS, FRAXA & Autism Speaks
– Baylor Medical Center – Behavioral Research
– Vanderbilt University – Drug Discovery
– Correlagen Diagnostics – Companion Diagnostic
Basic Research
Prototype Design or Discovery
Preclinical Development
Clinical DevelopmentFDA Filing/ Approval &
Launch Preparation
The Development Pipeline and Valley of Death
Basic Research
[Mostly NIH Funded]
Prototype Design or Discovery
Preclinical Development
Clinical Development[Mostly Large Pharma]
FDA Filing/ Approval &
Launch Preparation
The Development Pipeline and Valley of Death
[Inconsistent Funding]
[Inconsistent Funding]
The Development Pipeline and Valley of DeathVarious Solutions
Prototype Design or Discovery
Preclinical Development
Clinical Development[Mostly Large Pharma]
FDA Filing/ Approval &
Launch Preparation
Private Foundation Research
NIH - SBIR
Venture Philanthropy
[Inconsistent Funding]
[Inconsistent Funding]
NIH – CTSA’s
TATRC
Basic Research
[Mostly NIH Funded]
TRND
Related Documents
